Novo Nordisk has escalated its legal offensive against Eli Lilly, filing a request for a preliminary injunction to block the Indianapolis-based competitor from advertising its weight-loss drugs. Novo Nordisk alleges the company is using deceptive marketing and outdated studies to promote Mounjaro and Zepbound, deepening a high-stakes rivalry in the obesity treatment market. Meanwhile, Tenet Healthcare reported a robust second quarter, posting a profit of $826 million compared to $288 million a year prior. Following these results, the company raised its full-year earnings guidance to a range of $20.30 to $21.69 per share.

Beyond the boardroom, public health data paints a concerning picture. Confirmed measles cases in the U.S. reached 2,318 in the first seven months of the year, a three-decade high that eclipses the total count for 2025. CDC officials are simultaneously expanding an investigation into a multistate cyclospora outbreak linked to iceberg lettuce, now tracking cases across nine states including Illinois, Kansas, and Pennsylvania. In clinical developments, Ipsen faced a setback after its drug Bylvay failed to meet primary endpoints in a late-stage trial for biliary atresia in infants.